BNT162b2s01 / Pfizer, BioNTech, Fosun Pharma - LARVOL DELTA

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (clinicaltrials.gov) - P2/3 | N=47079 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects (clinicaltrials.gov) - P2 | N=137 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (clinicaltrials.gov) - P2/3 | N=46953 | Active, not recruiting | Sponsor: BioNTech SE | Trial completion date: Feb 2024 ➔ Feb 2023 | Trial primary completion date: Feb 2024 ➔ Feb 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (clinicaltrials.gov) - P2/3 | N=46949 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects (clinicaltrials.gov) - P2 | N=137 | Active, not recruiting | Sponsor: BioNTech SE | Trial completion date: Jul 2023 ➔ Oct 2022 | Trial primary completion date: Jul 2023 ➔ Apr 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (clinicaltrials.gov) - P2/3 | N=43998 | Recruiting | Sponsor: BioNTech SE | Trial completion date: May 2023 ➔ Feb 2024 | Trial primary completion date: May 2023 ➔ Feb 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects (clinicaltrials.gov) - P2; N=137; Active, not recruiting; Sponsor: BioNTech SE; Recruiting ➔ Active, not recruiting; N=549 ➔ 137

Clinical • Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (clinicaltrials.gov) - P2/3; N=43998; Recruiting; Sponsor: BioNTech SE; Phase classification: P3 ➔ P2/3

Clinical • Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects (clinicaltrials.gov) - P2; N=549; Recruiting; Sponsor: BioNTech SE; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (clinicaltrials.gov) - P2/3; N=43998; Recruiting; Sponsor: BioNTech SE; Trial primary completion date: Nov 2021 ➔ May 2023

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A trial testing the safety and effects of two vaccines in healthy adults (clinicaltrialsregister.eu) - P2; N=549; Ongoing; Sponsor: BioNTech SE

New P2 trial • Infectious Disease • Novel Coronavirus Disease

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty™ or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects (clinicaltrials.gov) - P2; N=549; Not yet recruiting; Sponsor: BioNTech SE

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases